BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 34170516)

  • 1. Recurrent cutaneous hyalohyphomycosis secondary to Purpureocillium lilacinum in an immunocompetent individual.
    McGeachie DL; Boyce AE; Miller RM
    Australas J Dermatol; 2021 Aug; 62(3):e411-e413. PubMed ID: 34170516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cutaneous infection caused by Purpureocillium lilacinum: Case reports and literature review of infections by Purpureocillium and Paecilomyces in Taiwan.
    Lu KL; Wang YH; Ting SW; Sun PL
    J Dermatol; 2023 Aug; 50(8):1088-1092. PubMed ID: 37082787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cutaneous hyalohyphomycosis caused by Purpureocillium lilacinum in an immunocompetent patient: case report and review.
    Saghrouni F; Saidi W; Ben Said Z; Gheith S; Ben Said M; Ranque S; Denguezli M
    Med Mycol; 2013 Aug; 51(6):664-8. PubMed ID: 23330674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cutaneous hyalohyphomycosis caused by Paecilomyces lilacinus in an immunocompetent host successfully treated with itraconazole: case report and review.
    Gutiérrez-Rodero F; Moragón M; Ortiz de la Tabla V; Mayol MJ; Martín C
    Eur J Clin Microbiol Infect Dis; 1999 Nov; 18(11):814-8. PubMed ID: 10614958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An unusual case of hyalohyphomycosis due to
    Raghavan R; Chithra G; Fernandez S; Shamana Suryanarayana B; Singh R
    Curr Med Mycol; 2018 Jun; 4(2):36-39. PubMed ID: 30324156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful Treatment of Recurrent Cutaneous Purpureocillium lilacinum (Paecilomyces lilacinus) Infection with Posaconazole and Surgical Debridement.
    Chen WY; Lin SR; Hung SJ
    Acta Derm Venereol; 2019 Dec; 99(13):1313-1314. PubMed ID: 31532536
    [No Abstract]   [Full Text] [Related]  

  • 7. Purpureocillium lilacinum tattoo-related skin infection in a kidney transplant recipient.
    Trinh SA; Angarone MP
    Transpl Infect Dis; 2017 Jun; 19(3):. PubMed ID: 28273390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Purpureocillium lilacinum an emergent pathogen: antifungal susceptibility of environmental and clinical strains.
    Corrêa-Moreira D; de Lima Neto RG; da Costa GL; de Moraes Borba C; Oliveira MME
    Lett Appl Microbiol; 2022 Jul; 75(1):45-50. PubMed ID: 35342967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous hyalohyphomycosis caused by Paecilomyces lilacinus: report of three cases and review of the literature.
    Hall VC; Goyal S; Davis MD; Walsh JS
    Int J Dermatol; 2004 Sep; 43(9):648-53. PubMed ID: 15357743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous hyalohyphomycosis due to Purpureocillium lilacinum in an immunocompromised patient after renal transplantation.
    Demitsu T; Nagashima K; Okabe T; Morisawa Y; Ishikawa N; Yagisawa T; Fukuta H; Ohtsuki M; Kano R; Harada K
    J Dermatol; 2017 Jun; 44(6):725-726. PubMed ID: 27461556
    [No Abstract]   [Full Text] [Related]  

  • 11. Fatal hyalohyphomycosis with cutaneous involvement caused by Purpureocillium lilacinum in an immunocompromised patient with bullous pemphigoid.
    Corbeddu M; Ferreli C; Cappai R; Ferraguti P; Atzori L; Pilloni L; Rongioletti F
    Acta Biomed; 2021 Jul; 92(3):e2021139. PubMed ID: 34212928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neglected and emerging fungal infections: review of hyalohyphomycosis by Paecilomyces lilacinus focusing in disease burden, in vitro antifungal susceptibility and management.
    Antas PR; Brito MM; Peixoto É; Ponte CG; Borba CM
    Microbes Infect; 2012 Jan; 14(1):1-8. PubMed ID: 21907304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of antibody to Purpureocillium lilacinum by immunofluorescent assay and flow cytometry in serum of infected C57BL/6 mice.
    de Sequeira DC; Peixoto ML; De Luca PM; Oliveira-Ferreira J; Antas PR; Borba CM
    J Immunol Methods; 2013 Oct; 396(1-2):147-51. PubMed ID: 23872615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of voriconazole for the treatment of Paecilomyces lilacinus cutaneous infections: case presentation and review of published literature.
    Rimawi RH; Carter Y; Ware T; Christie J; Siraj D
    Mycopathologia; 2013 Apr; 175(3-4):345-9. PubMed ID: 23334554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others.
    Tortorano AM; Richardson M; Roilides E; van Diepeningen A; Caira M; Munoz P; Johnson E; Meletiadis J; Pana ZD; Lackner M; Verweij P; Freiberger T; Cornely OA; Arikan-Akdagli S; Dannaoui E; Groll AH; Lagrou K; Chakrabarti A; Lanternier F; Pagano L; Skiada A; Akova M; Arendrup MC; Boekhout T; Chowdhary A; Cuenca-Estrella M; Guinea J; Guarro J; de Hoog S; Hope W; Kathuria S; Lortholary O; Meis JF; Ullmann AJ; Petrikkos G; Lass-Flörl C; ;
    Clin Microbiol Infect; 2014 Apr; 20 Suppl 3():27-46. PubMed ID: 24548001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Keratomycosis due to
    Juyal D; Pal S; Sharma M; Negi V; Adekhandi S; Tyagi M
    Indian J Pathol Microbiol; 2018; 61(4):607-609. PubMed ID: 30303164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutaneous hyalohyphomycosis caused by Paecilomyces lilacinus successfully treated by oral voriconazole and nystatin packing.
    Huang CY; Sun PL; Tseng HK
    Mycopathologia; 2011 Aug; 172(2):141-5. PubMed ID: 21424606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Posaconazole in the treatment of refractory
    Almeida Oliveira M; Carmo A; Rosa A; Murta J
    BMJ Case Rep; 2019 Apr; 12(4):. PubMed ID: 30975779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cutaneous Hyalohyphomycosis and Its Atypical Clinical Presentations in Immunosuppressed Patients.
    Ferara N; Špoljar S; Lugović-Mihić L; Gverić Grginić A; Rezo Vranješ V; Bešlić I; Perović J; Regović Džombeta T
    Life (Basel); 2024 Jan; 14(1):. PubMed ID: 38276283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Invasive infections with Purpureocillium lilacinum: clinical characteristics and outcome of 101 cases from FungiScope® and the literature.
    Sprute R; Salmanton-García J; Sal E; Malaj X; Ráčil Z; Ruiz de Alegría Puig C; Falces-Romero I; Barać A; Desoubeaux G; Kindo AJ; Morris AJ; Pelletier R; Steinmann J; Thompson GR; Cornely OA; Seidel D; Stemler J;
    J Antimicrob Chemother; 2021 May; 76(6):1593-1603. PubMed ID: 33599275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.